# A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

> **NCT04522180** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** GHR-LRX

## Key facts

- **NCT ID:** NCT04522180
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-04
- **Primary completion:** 2022-07-15
- **Final completion:** 2023-05-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522180, "A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04522180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*